Clinical Trials Browser

NCT07085728 2025-08-22

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

Phase 2 Not yet recruiting

74 enrolled

Plasma cell

Multiple Myeloma

NCT05123131 2025-07-08

Isa-RVD

Phase 2 Active not recruiting

54 enrolled

Plasma cell

Multiple Myeloma

NCT04166565 2025-04-17

EMN19

Phase 2 Active not recruiting

41 enrolled

Plasma cell

Multiple Myeloma

NCT01415752 2025-04-08

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

Phase 2 Active not recruiting

373 enrolled 14 charts

Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT06189833 2024-04-23

TAURUS

Phase 2 Recruiting

200 enrolled

Plasma cell

Multiple Myeloma

NCT01190787 2024-01-23

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

Phase 2 Completed

150 enrolled

Plasma cell

Disease, Multiple Myeloma

NCT01913730 2023-12-13

Maintenance Therapy With Subcutaneous Bortezomib

Phase 2 Completed

63 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT00030875 2023-08-04

Bortezomib in Treating Patients With Mantle Cell Lymphoma

Phase 2 Completed

30 enrolled

Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT00377052 2023-08-04

Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma

Phase 2 Completed

29 enrolled

Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT01216683 2023-06-29

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Phase 2 Completed

289 enrolled 34 charts

Lymphoid

Lymphoma, Lymphoma, Follicular

NCT01045681 2020-12-07

BVD

Phase 2 Completed

75 enrolled

Plasma cell

Multiple Myeloma

NCT02219178 2020-07-17

Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Completed

42 enrolled

Plasma cell

Multiple Myeloma

NCT00124579 2018-08-09

S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Terminated

7 enrolled 6 charts

Plasma cell

Multiple Myeloma

NCT00458913 2018-07-12

Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma

Phase 2 Completed

82 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT00376961 2017-11-06

S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 2 Completed

68 enrolled 9 charts

Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT00723658 2015-03-06

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

Phase 2 Withdrawn

Lymphoid

Lymphoma, Waldenstrom Macroglobulinemia

NCT01055301 2015-03-06

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Withdrawn

Plasma cell

Multiple Myeloma

NCT00832234 2015-02-18

BDR-WM

Phase 2 Completed

59 enrolled

Lymphoid

Waldenstrom Macroglobulinemia

NCT00513877 2014-12-31

Bortezomib in Treating Patients With Malignant Pleural Mesothelioma

Phase 2 Completed

33 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT00814541 2014-12-31

PAD. ICORG 05-01, V11

Phase 2 Completed

53 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell